Status:

COMPLETED

Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis

Lead Sponsor:

Maulana Azad Medical College

Conditions:

Pulmonary Tuberculosis

Eligibility:

All Genders

10-70 years

Brief Summary

N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) are two drug metabolizing enzymes. Antituberculosis drug isoniazid is acetylated by NAT2 and forms ultimately a nontoxic compound which is m...

Eligibility Criteria

Inclusion

  • Patients with pulmonary tuberculosis
  • Patients receiving conventional antituberculosis drugs
  • Patients who directly presented with antituberculosis drug induced hepatitis

Exclusion

  • Habitual alcohol drinkers
  • Patients with evidence of viral hepatitis

Key Trial Info

Start Date :

September 1 2005

Trial Type :

OBSERVATIONAL

End Date :

September 1 2008

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00834353

Start Date

September 1 2005

End Date

September 1 2008

Last Update

February 3 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Premashis Kar

New Delhi, New Delhi, India, 110002